United Therapeutics Inks $216 Million Merger With SteadyMed

United Therapeutics and SteadyMed announced a merger agreement under which United Therapeutics will acquire the specialty pharmaceutical startup that fought to invalidate its patents in the past.

The transaction is valued at a total of $216 million, including $75 million contingent upon United Therapeutics’ commercialization of Trevyent (treprostinil), a rival product it will acquire from SteadyMed through the merger that is used to treat pulmonary arterial hypertension.

The transaction must await termination of the required waiting period under the Antitrust Improvements Act and approval of SteadyMed’s shareholders. It is expected to be wrapped up in the third quarter of the year.